Innova Captab

Innova Captab EBIT CAGR 5Y

The EBIT CAGR (5 Year) of Innova Captab (INNOVACAP.NS) as of Nov 22, 2026 is 27.87 %. In the previous year, EBIT CAGR (5 Year) was 27.87 % — a change of 0.00% (lower).

EBIT CAGR 5Y

27.87 %

YoY

0.00%

Last updated:

EBIT CAGR (5 Year) of Innova Captab is 2026 27.87 % . EBIT CAGR (5 Year) of Innova Captab was 2025 27.87 % . It decreases by 0.00% lower compared to the previous year.

The Innova Captab EBIT CAGR 5Y history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT CAGR 5Y
Date
EBIT CAGR 5Y
Jan 1, 2019
27.87 INR
Jan 1, 2020
27.87 INR
Jan 1, 2021
27.87 INR
Jan 1, 2022
27.87 INR
Jan 1, 2023
27.87 INR
Jan 1, 2024
27.87 INR
Jan 1, 2025
27.87 INR
Jan 1, 2026
27.87 INR
The Innova Captab EBIT CAGR 5Y history
YEAREBIT CAGR 5YYoY
27.87 %0.00%
27.87 %0.00%
27.87 %0.00%
27.87 %0.00%
27.87 %0.00%
27.87 %0.00%
27.87 %0.00%
27.87 %0.00%
27.87 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Innova Captab Stock analysis

What does Innova Captab do? Innova Captab Ltd generates revenue through its CDMO business, which offers research, product development, and manufacturing services to clients in the pharmaceutical sector. The company also earns from its domestic branded generics business, developing, manufacturing, and distributing generic formulation products under its own brand names across India via online and offline channels. Additionally, Innova Captab sells its generic drug products through various e-commerce pharmacy sites. The company's diversified portfolio includes tablets, capsules, dry syrups, dry powder injection, ointments, and liquid orals. Its international branded generic product business focuses on exporting branded generic products globally. Innova Captab's primary customers are pharmaceutical companies seeking CDMO services, Indian consumers purchasing generic medicines through retail and online pharmacies, and international buyers of branded generic products. The domestic market segment is served through branded generics sold under the company's own brand names, while the international segment targets global markets for branded generic drug exports. The company's value chain spans research and development, manufacturing, drug distribution, marketing, and exports, ensuring comprehensive coverage across the pharmaceutical industry. The company's product segments include CDMO services, domestic branded generics, and international branded generics. CDMO services are provided to pharmaceutical firms requiring outsourced research and manufacturing. Domestic branded generics are marketed in India under the company's brand names through both online and offline channels. International branded generics are exported to global markets, leveraging the company's manufacturing capabilities and product portfolio. Innova Captab's business model integrates all stages of the pharmaceutical value chain, from R&D to exports, to deliver a full-service solution for its clients and customers. Innova Captab is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Innova Captab stock

EBIT CAGR (5 Year) of Innova Captab is 27.87 % in 2026.

On Eulerpool you can find the complete historical development of EBIT CAGR (5 Year) Innova Captab since 2006 – with annual values, charts, and detailed analysis.

The 5-year EBIT CAGR shows the compound annual growth rate of EBIT over the past five years.

To evaluate EBIT CAGR (5 Year)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EBIT CAGR (5 Year).

EBIT CAGR (5 Year)'s is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBIT CAGR (5 Year)'s Innova Captab historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Growth — Innova Captab

All Key Metrics — Innova Captab